High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 9, 2011, Pages 1053-1058

  Zelinkova, Z ^a   De Haar, C ^a   De Ridder, L ^a   Pierik, M J ^b   Kuipers, E J ^a   Peppelenbosch, M P ^a   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG SAFETY; ENTERITIS; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOMODULATION; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UTERUS; YOUNG ADULT;

EID: 79953689910     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04617.x     Document Type: Article

References (21)

1. Zelinkova Z, Mensink PB, Dees J, et al. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010; 45: 46-50.
2. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92. (Pubitemid 40039370)
3. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn's disease: data from 5000-patients TREAT registry. Gastroenterology 2004; 126: A54.
4. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-8. (Pubitemid 44512222)
5. Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007; 132: A144.
6. Kane SV, Acquah LA,. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-33.
7. Gisbert JP,. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881-95.
8. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn's Colitis 2010; 4: 63-101.
9. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immnosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 169-74. (Pubitemid 44314944)
10. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011 [Epub ahead of print].
11. Finley WH, Gustavson KH, Hall TM, et al. Birth defect surveillance: Jefferson County, Alabama, and Uppsala County, Sweden. South Med J 1994; 87: 440-5. (Pubitemid 24118302)
12. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA,. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551-63. (Pubitemid 29501961)
13. Kane S, Ford J, Cohen R, Wagner C,. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-6.
14. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170: 3528-33. (Pubitemid 36359219)
15. Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 2009; 31: 223-36.
16. Simister NE,. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-9. (Pubitemid 36792087)
17. Pentsuk N, van der Laan JW,. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009; 86: 328-44.
18. Mahadevan U, Kane SV, Church JA, et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008; 134: A69.
19. Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohn's Colitis 2010; 4: 603-5.
20. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J,. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13: 1024-30. (Pubitemid 47309975)
21. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523-9.